Please assess the completion status of the following clinical trial:

Trial Title: Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Myocardial rest/regadenoson stress perfusion PET study within 60 days~* Normal rest LVEF (greater than or equal to 50%)~* No change in symptoms or treatment between the PET and the MRI study~* Willing to consent to the study~* Male or female who is either post-menopausal, surgically sterile, or if has a childbearing potential, a negative pregnancy test within 2 days prior to the MRI study.~Exclusion Criteria:~* Renal dysfunction (estimated glomerular filtration rate \< 60 mL/min/1.73m2) within 6 months~* Metallic implants, pacemaker, blood vessel clip (contra-indicated for MRI)~* Patient size exceeds MRI bore/table limits: (Max body diameter \> 60 cm, weight \> 136 kg)~* History of gadolinium contrast allergy or intolerance~* Second or third degree AV block~* Sinus node dysfunction~* Acute myocardial infarction (past 3 months)~* Actively wheezing or with acute asthma or bronchospastic attacks requiring changes in therapy within the past 30 days~* Patients that have experienced a previous hypersensitivity reaction thought to be related to regadenoson

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Regadenoson (Type: OTHER): Regadenoson is a single-use, pre-filled syringe containing 0.4 mg/5 mL of regadenoson.

Based on this trial design, predict the completion outcome and termination type (if applicable).